Search

Your search keyword '"Psoriatic arthritis -- Care and treatment"' showing total 15 results
Start Over Descriptor "Psoriatic arthritis -- Care and treatment" Publisher plus media
15 results on '"Psoriatic arthritis -- Care and treatment"'

1. Psoriatic Arthritis Disease Overview, Epidemiology and Disease Management Forecasts

Subjects
Tumor necrosis factor -- Forecasts and trends -- Reports, Epidemiology -- Reports -- Forecasts and trends, Psoriatic arthritis -- Care and treatment, Company business management, Market trend/market analysis, General interest, News, opinion and commentary
Abstract

DUBLIN: Research and Markets has issued the following news release: The 'Psoriatic Arthritis: Global Drug Forecast and Market Analysis to 2028' report has been added to ResearchAndMarkets.com's offering. Current therapies [...]

Published
2020

2. Novartis Cosentyx shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind study

Subjects
Novartis AG, Secukinumab, Psoriatic arthritis -- Care and treatment, Synovitis -- Care and treatment, General interest, News, opinion and commentary, American College of Rheumatology, Cosentyx (Medication)
Abstract

Basel: Novartis AG has issued the following press release: Novartis, a leader in rheumatology and immuno-dermatology, today announced 12-week results from the first-of-its-kind Phase IIIb ULTIMATE randomized controlled trial, which [...]

Published
2020

3. MorphoSys' Licensee Janssen Receives CHMP Positive Opinion for Tremfya(R) (guselkumab) for Treatment of Adults with Active Psoriatic Arthritis (PsA) in the European Union (EU)

Subjects
MorphoSys AG, Guselkumab, Biotechnology industries, Psoriatic arthritis -- Care and treatment, Biological products industry, Antiarthritic agents, Adults, General interest, News, opinion and commentary, European Union, Tremfya (Medication)
Abstract

PLANEGG: MorphoSys AG has issued the following news release: MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) announced today that its licensee Janssen Research & Development, [...]

Published
2020

4. Positive Trial Results with Filgotinib in Psoriatic Arthritis and Ankylosing Spondylitis Both Published in The Lancet (Updated on 22-10-18)

Subjects
Gilead Sciences Inc. -- Product development, Ankylosing spondylitis -- Care and treatment, Psoriatic arthritis -- Care and treatment, Biological products industry -- Product development, Antiarthritic agents -- Product development, General interest, News, opinion and commentary
Abstract

CHICAGO: Gilead Sciences, Inc. has issued the following press release: Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that detailed results from two clinical [...]

Published
2018

5. POSITIVE TRIAL RESULTS WITH FILGOTINIB IN PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS BOTH PUBLISHED IN THE LANCET

Subjects
Gilead Sciences Inc. -- Product development, Ankylosing spondylitis -- Care and treatment, Psoriatic arthritis -- Care and treatment, Biological products industry -- Product development, Antiarthritic agents -- Product development, General interest, News, opinion and commentary
Abstract

BELGIUM: Galapagos NV has issued the following press release: Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that detailed results from two clinical trials [...]

Published
2018

6. Novartis 5-year data in psoriatic arthritis and ankylosing spondylitis reinforces Cosentyx(r) leadership in spondyloarthritis

Subjects
Novartis AG, Ankylosing spondylitis -- Care and treatment, Pharmaceutical industry, Psoriatic arthritis -- Care and treatment, General interest, News, opinion and commentary, Cosentyx (Medication)
Abstract

Zurich, Switzerland: SIX Swiss Exchange Ltd has issued the following notice: Novartis, a leader in immuno-dermatology and rheumatology, announced today it will be presenting five-year data from the ongoing extensions [...]

Published
2018

7. MorphoSys Announces Approval of Tremfya(R) (Guselkumab) for the Treatment of Moderate to Severe Forms of Psoriasis and Psoriatic Arthritis in Japan

Subjects
MorphoSys AG, Monoclonal antibodies, Biotechnology industries, Psoriatic arthritis -- Care and treatment, Biological products industry, General interest, News, opinion and commentary, Tremfya (Medication)
Abstract

Planegg, Germany : MorphoSys has issued the following press release: MorphoSys Announces Approval of Tremfya(R) (Guselkumab) for the Treatment of Moderate to Severe Forms of Psoriasis and Psoriatic Arthritis in [...]

Published
2018

8. MorphoSys Announces Approval of Tremfya(R) (Guselkumab) for the Treatment of Moderate to Severe Forms of Psoriasis and Psoriatic Arthritis in Japan

Subjects
MorphoSys AG, Monoclonal antibodies, Biotechnology industries, Psoriatic arthritis -- Care and treatment, Biological products industry, General interest, News, opinion and commentary, Tremfya (Medication)
Abstract

Planegg, Germany : MorphoSys has issued the following press release: MorphoSys Announces Approval of Tremfya(R) (Guselkumab) for the Treatment of Moderate to Severe Forms of Psoriasis and Psoriatic Arthritis in [...]

Published
2018

9. Oral OTEZLA(r)V (Apremilast) Receives Positive Nice Recommendation for Adults with Psoriatic Arthritis

Subjects
Celgene Corp., Chronic diseases -- Care and treatment, Pharmaceutical industry, Psoriatic arthritis -- Care and treatment, Antiarthritic agents, Adults, General interest, News, opinion and commentary, Otezla (Medication)
Abstract

Summit:Celgene Corporation.has issued the following press release: Celgene announced today that the National Institute for Health and Care Excellence (NICE) has issued a final appraisal determination (FAD) recommending the use [...]

Published
2017

10. Oral OTEZLA(r)V (Apremilast) Receives Positive Nice Recommendation for Adults with Psoriatic Arthritis

Subjects
Celgene Corp., Chronic diseases -- Care and treatment, Pharmaceutical industry, Psoriatic arthritis -- Care and treatment, Antiarthritic agents, Adults, General interest, News, opinion and commentary, Otezla (Medication)
Abstract

Summit:Celgene Corporation.has issued the following press release: Celgene announced today that the National Institute for Health and Care Excellence (NICE) has issued a final appraisal determination (FAD) recommending the use [...]

Published
2017

11. Oral OTEZLA(r)V (Apremilast) Receives Positive Nice Recommendation for Adults with Psoriatic Arthritis

Subjects
Celgene Corp., Chronic diseases -- Care and treatment, Pharmaceutical industry, Psoriatic arthritis -- Care and treatment, Antiarthritic agents, Adults, General interest, News, opinion and commentary, Otezla (Medication)
Abstract

Summit:Celgene Corporation.has issued the following press release: Celgene announced today that the National Institute for Health and Care Excellence (NICE) has issued a final appraisal determination (FAD) recommending the use [...]

Published
2016

12. Oral OTEZLA(r)V (Apremilast) Receives Positive Nice Recommendation for Adults with Psoriatic Arthritis

Subjects
Microsoft Corp., Chronic diseases -- Care and treatment, Software industry, Psoriatic arthritis -- Care and treatment, Antiarthritic agents, Adults, General interest, News, opinion and commentary, Otezla (Medication)
Abstract

Redmond: Microsoft has issued the following news release: Celgene announced today that the National Institute for Health and Care Excellence (NICE) has issued a final appraisal determination (FAD) recommending the [...]

Published
2016

13. First-Ever Psoriatic Arthritis Awareness Day Aims to Educate on Importance of Early Diagnosis and Treatment

Subjects
Celgene Corp. -- Public relations, Activities of daily living, Pharmaceutical industry -- Public relations, Psoriatic arthritis -- Care and treatment, Company public relations, General interest, News, opinion and commentary, National Psoriasis Foundation
Abstract

Summit:Celgene Corporation.has issued the following press release: Celgene Corporation (NASDAQ: CELG) and the National Psoriasis Foundation (NPF) have united to mark Wednesday, September 28th as the first-ever Psoriatic Arthritis (PsA) [...]

Published
2016

14. First-Ever Psoriatic Arthritis Awareness Day Aims to Educate on Importance of Early Diagnosis and Treatment

Subjects
Celgene Corp. -- Public relations, Activities of daily living, Pharmaceutical industry -- Public relations, Psoriatic arthritis -- Care and treatment, Company public relations, General interest, News, opinion and commentary, National Psoriasis Foundation
Abstract

Summit:Celgene Corporation.has issued the following press release: Celgene Corporation (NASDAQ: CELG) and the National Psoriasis Foundation (NPF) have united to mark Wednesday, September 28th as the first-ever Psoriatic Arthritis (PsA) [...]

Published
2016

15. First-Ever Psoriatic Arthritis Awareness Day Aims to Educate on Importance of Early Diagnosis and Treatment

Subjects
Celgene Corp. -- Public relations, Activities of daily living, Pharmaceutical industry -- Public relations, Psoriatic arthritis -- Care and treatment, Company public relations, General interest, News, opinion and commentary, National Psoriasis Foundation
Abstract

Summit:Celgene Corporation.has issued the following press release: Celgene Corporation (NASDAQ: CELG) and the National Psoriasis Foundation (NPF) have united to mark Wednesday, September 28th as the first-ever Psoriatic Arthritis (PsA) [...]

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results